Stifel Nicolaus analyst Thomas Stephan maintained a Buy rating on Sight Sciences (SGHT – Research Report) on November 10 and set a price target of $3.00. The company’s shares closed last Friday at $1.76.
According to TipRanks, Stephan is an analyst with an average return of -22.6% and a 18.18% success rate. Stephan covers the Healthcare sector, focusing on stocks such as Staar Surgical, Sight Sciences, and Glaukos.
The word on The Street in general, suggests a Hold analyst consensus rating for Sight Sciences with a $4.88 average price target.
See today’s best-performing stocks on TipRanks >>
Based on Sight Sciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $20.01 million and a GAAP net loss of $13.04 million. In comparison, last year the company earned a revenue of $18.68 million and had a GAAP net loss of $22.23 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sight Sciences (SGHT) Company Description:
Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company’s product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and viscoelastic delivery. The company’s non-surgical product portfolio consists of TearCare system which is commercially available for both ophthalmologists and optometrists.
Read More on SGHT:
- Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023
- Disaster for Sight Services (NASDAQ:SGHT): Shares Fall on Medicare Concerns
- Piper says WPS update ‘massive blow’ to Sight Sciences, good news for Glaukos
- Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting
- Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
